

DAFTAR PUSTAKA

- ACE inhibitors: their properties and use in hypertension, 2010. . *Prescriber*, **21**: 39–41.
- Alcocer LA, Bryce A, De Padua Brasil D, Lara J, Cortes JM, Quesada D, Rodriguez P., 2023. The Pivotal Role of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers in Hypertension Management and Cardiovascular and Renal Protection: A Critical Appraisal and Comparison of International Guidelines. *Am J Cardiovasc Drugs*, **23**(6): 663-682.
- Alfian, R., Susanto, Y., dan Khadizah, S., 2017. Kualitas Hidup Pasien Hipertensi Dengan Penyakit Penyerta Di Poli Jantung RSUD Ratu Zalecha Martapura. *Jurnal Pharmascience*, **04**: 210-218.
- Almadfaa, R.O., Wigle, P.R., Hincapie, A.L., dan Guo, J.J., 2023. The Utilization, Expenditure, and Price of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers in the US Medicaid Programs: Trends Over a 31 Year Period. *International Journal of Cardiology*, **370**: 412–418.
- Andayani, T. M., 2013, Farmakoekonomi: Prinsip dan Metodologi, 13-17, *Bursa Ilmu*, Yogyakarta.
- Anonim, 2020, Selamat Datang di RSGM Ambarawa “Kesembuhan dan Kepuasan Anda adalah Kebahagiaan Kami”, diambil dari <http://rsudambarawa.semarangkab.go.id/>, diakses pada bulan Maret 2023.
- Baroroh, F., Fathonah, S. S., 2017, Biaya Medik Langsung Terapi Hipertensi Pasien Rawat Jalan Di Rumah Sakit X Yogyakarta, *Jurnal Farmasi Sains dan Praktis*, **3**(2): 6-13.
- Borghi, C., Cicero, A.F., Agnoletti, D., dan Fiorini, G., 2023. Pathophysiology of cough with angiotensin-converting enzyme inhibitors: How to explain within-class differences?. *European Journal of Internal Medicine*, **110**: 10–15.
- Brown N.J., Kumar S., Painter C.A., Vaughan D.E., 2002. ACE inhibition Versus Angiotensin Type 1 Receptor Antagonism: Differential Effects on PAI-1 Over Time. *Hypertension*. Dec; **40**(6): 859-65.
- Budweg, J., Ahmed, M.M., Vilaro, J.R., Al-Ani, M.A., Aranda, J.M., Guo, Y., dkk., 2024. Combination diuretic therapies in heart failure: Insights from GUIDE-IT. *American Heart Journal Plus: Cardiology Research and Practice*, **45**: 100436.

- Carretero, O.A., 2005. Novel mechanism of action of ACE and its inhibitors. *American Journal of Physiology-Heart and Circulatory Physiology*, **289**: 1796–1797.
- Carroll, C.A., Coen, M.M., dan Piepho, R.W., 2003. Economic Impact of Ramipril on Hospitalization of High-Risk Cardiovascular Patients. *Annals of Pharmacotherapy*, **37**: 327–331.
- Cernes, R., Mashavi, M., Zimlichman, R., 2011, Differential Clinical Profile of Candesartan Compared to Other Angiotensin Receptor Blockers, *Dove Press Journal: Vascular Health and Risk Management*, **7**: 749-759.
- Chen, R., Suchard, M.A., Krumholz, H.M., Schuemie, M.J., Shea, S., Duke, J., dkk., 2021. Comparative First-Line Effectiveness and Safety of ACE (Angiotensin-Converting Enzyme) Inhibitors and Angiotensin Receptor Blockers: A Multinational Cohort Study. *Hypertension*, **78**: 591–603.
- Chobanian, A.V., Bakris, G.L., Black, H.R., Cushman, W.C., Green, L. A., Izzo, J. L. Jr., dkk., 2003. National Heart, Lung, and Blood Institute Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure; National High Blood Pressure Education Program Coordinating Committee. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. *JAMA*, **289**(19), 2560-72.
- Da Silva, P.M., 2010. Efficacy of Fixed-Dose Combination Therapy in the Treatment of Patients with Hypertension: Focus on Amlodipine/Valsartan. *Clinical Drug Investigation*, **30**: 625–641.
- Delacroix, S. dan Chokka, R.G., 2014. Hypertension: Pathophysiology and Treatment. *Journal of Neurology & Neurophysiology*, **5**(6), 1-8.
- Dinas Kesehatan Provinsi Jawa Tengah. 2020. Profil Kesehatan Provinsi Jawa Tengah Tahun 2019.
- Escobar, J., Rawat, A., Maradiaga, F., Isaak, A.K., Zainab, S., Arusi Dari, M., dkk., 2023. Comparison of Outcomes Between Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers in Patients With Myocardial Infarction: A Meta-Analysis. *Cureus*, **5**(10): e47954.
- Fauziah, N., Indah, K. K., Kusuma, I. Y., 2024. Analisis Minimalisasi Biaya (AMiB) Antihipertensi Irbesartan dengan Candesartan pada Pasien Hipertensi Rawat Jalan. *Journal of Pharmaceutical and Health Research*, **5**(3):1-8.
- Fukuda, M. dan Kimura, G., 2006. Pathophysiology of Antihypertensive Therapy with Diuretics. *Hypertension Research*, **29**: 645–653.

- Gallo, G., Volpe, M., dan Rubattu, S., 2022. Angiotensin Receptor Blockers in the Management of Hypertension: A Real-World Perspective and Current Recommendations. *Vascular Health and Risk Management*, **18**: 507–515.
- Hara, M., Sakata, Y., Nakatani, D., Suna, S., Usami, M., Matsumoto, S., dkk., 2014. Comparison of 5-Year Survival After Acute Myocardial Infarction Using Angiotensin-Converting Enzyme Inhibitor Versus Angiotensin II Receptor Blocker. *The American Journal of Cardiology*, **114**: 1–8.
- Iqbal, A.M., Jamal, S.F., 2022. Essential Hypertension. *Treasure Island (FL)*, StatPearls Publishing.
- Julius, S., Nesbitt, S., Egan, B., Kaciroti, N., Schork, M. A., Grazinski, M., Michelson, E., 2004. Trial of Preventing Hypertension: Design and 2-Year Progress Report. *American Heart Association, Inc.*, **44**: 146-151.
- Kementerian Kesehatan, 2018, Hipertensi, The Silent Killer, diambil dari <https://p2ptm.kemkes.go.id/infographic-p2ptm/hipertensi-penyakit-jantung-dan-pembuluh-darah/hipertensi-the-silent-killer>, diakses pada bulan Maret 2023.
- Kementerian Kesehatan, 2019, Hipertensi Penyakit Paling Banyak Diidap Masyarakat, diambil dari <https://www.kemkes.go.id/article/view/19051700002/hipertensi-penyakit-paling-banyak-diidap-masyarakat.html>, diakses pada bulan Maret 2023.
- Kementerian Kesehatan, 2021^a, *Keputusan Menteri Kesehatan Republik Indonesia Nomor HK.01.07/MENKES/4634/2021 tentang Pedoman Nasional Pelayanan Kedokteran Tata Laksana Hipertensi Dewasa*, Kementerian Kesehatan Republik Indonesia, Jakarta.
- Kementerian Kesehatan, 2021^b, *Keputusan Menteri Kesehatan Republik Indonesia Nomor HK.01.07/MENKES/4801/2021 tentang Pedoman Nasional Pelayanan Kedokteran Tata Laksana Gagal Jantung*, Kementerian Kesehatan Republik Indonesia, Jakarta.
- Kementerian Kesehatan, 2023, *Keputusan Menteri Kesehatan Republik Indonesia Nomor HK.01.07/MENKES/2197/2023 tentang Formularium Nasional*, Kementerian Kesehatan Republik Indonesia, Jakarta.
- Lee, E.M., 2023. Calcium Channel Blockers For Hypertension: Old, But Still Useful. *Cardiovascular Prevention and Pharmacotherapy*, **5**: 113–125.
- Li, E.C., Heran, B.S., dan Wright, J.M., 2014. Angiotensin converting enzyme (ACE) inhibitors versus angiotensin receptor blockers for primary hypertension. *Cochrane Database of Systematic Reviews*, **2014**: 1-44.

- Mancia, G., Kreutz, R., Brunström, M., Burnier, M., Grassi, G., Januszewicz, A., dkk., 2023. 2023 ESH Guidelines for the management of arterial hypertension The Task Force for the management of arterial hypertension of the European Society of Hypertension: Endorsed by the International Society of Hypertension (ISH) and the European Renal Association (ERA). *Journal of Hypertension*, **41**: 1874–2071.
- Mancia, G., Kreutz, R., Brunström, M., Burnier, M., Grassi, G., Januszewicz, A., dkk., 2023. 2023 ESH Guidelines for the management of arterial hypertension The Task Force for the management of arterial hypertension of the European Society of Hypertension: Endorsed by the International Society of Hypertension (ISH) and the European Renal Association (ERA). *Journal of Hypertension*, **41**: 1874–2071.
- Marhabatsar, N. S., Sijid, S. A., 2021. Review: Penyakit Hipertensi pada Sistem Kardiovaskular. *Journal UIN Alauddin*, 72-78.
- McDonagh, T. A., Metra, M., Adamo, M., Gardner, R.S., Baumbach, A., Böhm, M., dkk., 2021. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. *European Heart Journal*, **42**: 3599–3726.
- Morales-Olivas, F.J., 2024. Diuretics use in the management of hypertension. *Hipertensión y Riesgo Vascular*, **41**: 186–193.
- Nur, A.B., Suprapti, B., Yulistiani, Y., Yusuf, M., Kurniawati, N., 2023. Drug Cost Analysis of Outpatients with Cardiovascular Disease Under The National Health Insurance Scheme. *Pharmacy Education*, **23**(4): 1–4.
- Nurhikmawati, Afiifah, I., Syahrudin, F. I., Aspar, A., Lestari, I., 2024. Karakteristik Pasien Hipertensi dengan Gangguan Kardiovaskular. *Fakumi Medical Journal: Jurnal Mahasiswa Kedokteran*, **4**: 513–520.
- Ogihara, T., Saruta, T., Rakugi, H., Saito, I., Shimamoto, K., dkk., 2015. Combination therapy of hypertension in the elderly: a subgroup analysis of the Combination of OLMesartan and a calcium channel blocker or diuretic in Japanese elderly hypertensive patients trial. *Hypertension Research*, **38**: 89–96.
- Okpechi, I.G., Rayner, B.L., 2010. Update on The Role of Candesartan in The Optimal Management of Hypertension and Cardiovascular Risk Reduction. *Dove Press Journal: Integrated Blood Pressure Control*, **3**: 45-55.
- Oliver, E., Mayor Jr, F., D’Ocon, P., 2019. Beta-blockers: Historical Perspective and Mechanisms of Action. *Revista Española de Cardiología (English Edition)*, **72**: 853–862.

- Pinto, B., Jadhav, U., Singhai, P., Sadhanandham, S., Shah, N., 2020. ACEI-Induced Cough A Review of Current Evidence and Its Practical Implications for Optimal CV Risk Reduction, *Indian Heart Journal*, **72**: 345-350.
- Pebrisiana, P., Tambunan, L.N., dan Baringbing, E.P., 2022. Hubungan Karakteristik dengan Kejadian Hipertensi pada Pasien Rawat Jalan di RSUD Dr. Doris Sylvanus Provinsi Kalimantan Tengah: The Relationship of Characteristics with the Event of Hypertension in Outpatient Patients in RSUD Dr. Doris Sylvanus Central Kalimantan Province. *Jurnal Surya Medika*, **8**: 176–186.
- Peresuodei, T.S., Gill, A., Orji, C., Reghefaoui, M., Saavedra Palacios, M.S., dan Nath, T.S., 2024. A Comparative Study of the Safety and Efficacy Between Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers on the Management of Hypertension: A Systematic Review. *Cureus*, **16**(2): e54311.
- Petrie, J.R., Guzik, T.J., dan Touyz, R.M., 2018. Diabetes, Hypertension, and Cardiovascular Disease: Clinical Insights and Vascular Mechanisms. *Canadian Journal of Cardiology*, **34**: 575–584.
- Purwaningtyas, A.V., Barliana, M.I., 2021. Review: Efek Angiotensin Converting Enzyme Inhibitor (ACEI) Dan Angiotensin Receptor Blocker (ARB) Sebagai Kardioprotektor Terhadap Cardiovascular Events. *Farmaka Suplemen*, 76-87.
- Ram, C.V.S., 2010. Beta-Blockers in Hypertension. *The American Journal of Cardiology*, **106**: 1819–1825.
- Rehaban, S., 2022. Various Diuretiks and its Mechanism of Action. *J Pharma Reports*, **06**:151.
- Schmieder, R., 2005. Mechanisms for the Clinical Benefits of Angiotensin II Receptor Blockers. *American Journal of Hypertension*, **18**: 720–730.
- Shafie, A.A., Fen, N.C, Shabaruddin, F.H., Din, R.M., Yen, L.S., Lajis, R., Idrus, N. S., Wei, L. Y., dkk., 2019. Pharmacoeconomic Guideline For Malaysia. 2nd Edition. Ministry Of health Malaysia, Malaysia.
- Sleight, P., 2000. The HOPE Study (Heart Outcomes Prevention Evaluation). *Journal of the Renin-Angiotensin-Aldosterone System*, **I**: 18-20.
- Soenarta, A.A., Erwinarta, Mumpuni, A.S.S., Barack, R., Lukito, A.A., Hersunarti, N., Pratikto, R.S., 2015. Pedoman Tata Laksana Hipertensi pada Penyakit Kardiovaskular Vol. 1. Perhimpunan Dokter Spesialis Kardiovaskular Indonesia.

- Suchard, M.A., Krumholz, H.M., Schuemie, M.J., Shea, S., Duke, J., Pratt, N., Reich, C.G., Madigan D., You, S.C., Ryan, P.B., Hripcsak, G., 2021. Comparative First-Line Effectiveness and Safety of ACE (Angiotensin-Converting Enzyme) Inhibitors and Angiotensin Receptor Blockers : A Multinational Cohort Study. *American Heart Association, Inc.*, **78**: 591-603.
- Sun, W.P., Zhang, H.B., Guo, J.C., Zhang, X.K., Zhang, L.X., Li, C.L., Zhang, L., 2015. Comparison of the Efficacy and Safety of Different ACE Inhibitors in Patients With Chronic Heart Failure. *Medicine*, **95**(6): 1-8.
- Sweitzer, N.K., 2003. What Is an Angiotensin Converting Enzyme Inhibitor?. *Circulation*, **108**: e16-e18.
- Tai, C., Gan, T., Zou, L., Sun, Y., Zhang, Y., Chen, W., dkk., 2017. Effect of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers on cardiovascular events in patients with heart failure: a meta-analysis of randomized controlled trials. *BMC Cardiovascular Disorders*, **17**: 257.
- Tjandrawinata, R.R., 2016. Peran Farmakoekonomi dalam Penentuan Kebijakan yang Berkaitan dengan Obat-Obatan, **29**: 46-52.
- Tocci, G., Battistoni, A., Passerini, J., Musumeci, M.B., Francia, P., Ferrucci, A., dkk., 2015. Calcium Channel Blockers and Hypertension. *Journal of Cardiovascular Pharmacology and Therapeutics*, **20**: 121–130.
- Unger, T., Borghi, C., Charchar, F., Khan, N.A., Poukter, N.R., Prabhakaran, D., dkk., 2020. 2020 International Society of Hypertension Global Hypertension Practice Guidelines. *American Heart Association, Inc.*, **75**: 1334-1357.
- Williams B., Mancia G., Spiering W., Agabiti R.E., Azizi M., Burnier M., dkk., 2018. ESC Scientific Document Group 2018 ESC/ESH Guidelines for the management of arterial hypertension. *Eur Heart J*, Sep 1, **39**(33): 3021-3104.
- Young, J.S., Dunlap, M.E., Pfeffer, M.A., Probstfield, J.L., Cohen-Solal, A., Dietz, R., dkk., 2004. Mortality and Morbidity Reduction With Candesartan in Patients With Chronic Heart Failure and Left Ventricular Systolic Dysfunction: Result of the CHARM Low-Left Ventricular Ejection Fraction Trials. *American Heart Association, Inc.*, **110**: 2618-2626.
- Yunus, N., Adiputro, D.L., Biworo, A., Rudiansyah, M., dan Illiandri, O., 2022. Gambaran Pemberian Ace Inhibitor atau Angiotensin Receptor Blocker pada Pasien Gagal Jantung di RSUD Ulin Banjarmasin. *Homeostasis*, **5**: 311.

- Yusuf, S., Sleight, P., Pogue, J., Bosch, J., Davies, R., Dagenais, G., 2000. Effects of an Angiotensin-Converting-Enzyme Inhibitor, Ramipril, on Cardiovascular Events in High-Risk Patients. *The New England Journal of Medicine*, **342**(3): 145-153.
- Zhang Y, He D, Zhang W, Xing Y, Guo Y, Wang F, Jia J, Yan T, Liu Y, Lin S., 2020. ACE Inhibitor Benefit to Kidney and Cardiovascular Outcomes for Patients with Non-Dialysis Chronic Kidney Disease Stages 3-5: A Network Meta-Analysis of Randomised Clinical Trials. *Drugs*. **80**(8): 797-811.